Drug Profile
MP 112
Alternative Names: MP-112Latest Information Update: 19 Jan 2016
Price :
$50
*
At a glance
- Originator Marathon Pharmaceuticals
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Huntington's disease
Most Recent Events
- 19 Jan 2016 Discontinued - Phase-III for Huntington's disease in USA (unspecified route)